Taminato, T., Seino, Y., Goto, Y., Inoue, Y
This new medicine, generically called orforgipron, is a big win for Eli Lilly, potentially unlocking a worldwide market of millions more patients who want the convenience of a daily pill they can slot into their existing medicine regimen, at any hour of the day
Semaglutide works through a sophisticated mechanism of appetite suppression and metabolic regulation
The molecule was developed by the Australian pharmaceutical company Metabolic Pharmaceuticals (in collaboration with Monash University) and advanced through Phase I safety trials and a Phase IIb obesity efficacy trial enrolling approximately 900 participants in total
These concerns are completely valid and totally understandable